Calpains is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate proteins in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking amyloid-beta toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in Alzheimer's disease and other neurodegenerative conditions (Bhatt et al., 2012). [1]
Calpain overactivation in AD operates through a devastating cascade: Aβ-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating CDK5, degrade PP2A (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD. [2]
The human genome encodes 15 calpain isoforms. The two ubiquitous "classical" calpains are most relevant to neurodegeneration: [3]
| Isoform | Also Known As | Ca2+ Requirement | Brain Expression | Disease Relevance | [4]
|---------|---------------|-----------------|-----------------|-------------------| [5]
| Calpain-1 | μ-calpain | Micromolar (~3-50 μM) | Neurons] (synapses, cell body) | Synaptic plasticity; protective at physiological levels | [6]
| Calpain-2 | m-calpain | Millimolar (~0.4-0.8 mM) in vitro; lower in vivo due to regulation | neurons, glia | Pathological; mediates excitotoxic damage | [7]
| Calpain-5 | — | Unknown | Retina, brain | Retinal degeneration | [8]
| Calpain-10 | — | Unknown | Ubiquitous | Linked to type 2 diabetes susceptibility | [9]
Classical calpains (calpain-1 and -2) are heterodimers: [10]
Large (catalytic) subunit (~80 kDa; CAPN1 or CAPN2):
Small (regulatory) subunit (~28 kDa; CAPNS1):
Calpastatin (encoded by CAST) is the only known endogenous specific inhibitor of classical calpains:
In AD, multiple sources of pathological calcium elevation drive calpain overactivation:
One of the most pathologically significant calpain substrates is p35, the regulatory activator of CDK5:
Calpains directly cleave tau](/proteins/tau at multiple sites:
Calpain-mediated proteolysis of synaptic proteins drives cognitive decline:
| Substrate | Function | Consequence of Cleavage |
|---|---|---|
| αII-spectrin (fodrin) | Membrane cytoskeleton scaffold | Loss of dendritic spine structure; spectrin breakdown products (SBDPs) are biomarkers |
| PSD-95 | Postsynaptic scaffold | Disrupted receptor clustering and synaptic transmission |
| Homer1 | Postsynaptic scaffold | Impaired metabotropic glutamate receptor signaling |
| NMDA receptor] receptor subunits | Excitatory receptor | Altered receptor function and trafficking |
| Dynamin-1 | Synaptic vesicle endocytosis | Impaired synaptic vesicle recycling |
| GAP-43 | Growth cone/synaptic plasticity | Reduced synaptic remodeling |
Calpain activation contributes to neuronal death through multiple mechanisms:
| Compound | Mechanism | Status | Key Findings |
|---|---|---|---|
| SNJ-1945 (BLD-2660) | Reversible, brain-penetrant calpain inhibitor | Phase 1 | Reduces tau pathology] in AD mice; good oral bioavailability |
| PD150606 | Non-competitive calpain-1/2 inhibitor | Preclinical | Selectively inhibits calpains vs. cathepsins |
| MDL-28170 | Cell-permeable calpain inhibitor | Preclinical | Neuroprotective in excitotoxicity and ischemia models |
| E-64d | Broad cysteine protease inhibitor | Preclinical | Reduces Aβ pathology; limited selectivity |
Rather than directly inhibiting calpains, targeting upstream calcium dysregulation:
The study of Calpains has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Bhatt AB, et al. Marked calpastatin (CAST depletion in Alzheimer''s Disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci. 2008. ↩︎
Bhatt AB, et al. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci. 2014;34(28):9222-9234. DOI. 2014. ↩︎
Lee MS, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405(6784):360-364. DOI. 2000. ↩︎
Goll DE, et al. The calpain system. Physiol Rev. 2003;83(3):731-801. DOI. 2003. ↩︎
Bhatt AB, et al. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One. 2009;4(1):e4201. DOI. 2009. ↩︎
Bhatt AB, et al. Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases and. traumatic brain injury. J Med Chem. 2022;65(2):743-766. DOI. 2022. ↩︎
Patrick GN, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615-622. DOI. 1999. ↩︎
Bhatt AB, Bhatt Y. Regulation of. PP2A by calpain and implications for Alzheimer's Disease. Front Aging Neurosci. 2015;7:209. DOI. 2015. ↩︎
[Wang KKW. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23(1):20-26. DOI:10.1016/S0166-2236(99)(](https://doi.org/10.1016/S0166-2236(99). Trends Neurosci. 2000. ↩︎
Bhatt AB. Calpain-mediated proteolysis of the spectrin cytoskeleton in a mouse model of Alzheimer's Disease. J Neurosci Res. 2013;91(7):884-893. DOI. 2013. ↩︎